Introduction
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine that inhibits FGFR1, FGFR2 and FGFR3.
Like other prescription anticancer medicines, pemigatinib can cause side effects. These may range from manageable symptoms to adverse reactions requiring medical assessment, treatment interruption or dose modification.
The likelihood and severity of side effects vary between patients. They may also differ depending on the condition being treated, the treatment schedule, other medicines and individual health factors.
This page describes commonly reported adverse reactions and important safety concerns associated with pemigatinib.
Common Side Effects of Pemigatinib
Reported adverse reactions include:
- Hyperphosphatemia.
- Hair loss.
- Diarrhea.
- Nail disorders.
- Fatigue.
- Nausea.
- Constipation.
- Stomatitis.
- Dry eyes.
- Dry mouth.
- Decreased appetite.
- Vomiting.
- Changes in taste.
- Dry skin.
- Abdominal discomfort.
- Joint pain.
- Skin reactions.
Not every patient experiences these reactions. Some symptoms may be mild, while others may require medical treatment.
1. Hyperphosphatemia
Hyperphosphatemia is an increase in phosphate levels in the blood.
It is one of the important adverse reactions associated with pemigatinib because FGFR inhibition affects phosphate regulation.
Some patients may not experience noticeable symptoms, which is why laboratory monitoring is important.
If phosphate levels become significantly elevated, healthcare professionals may recommend dietary management, phosphate-lowering medicines or changes to the treatment schedule.
In some circumstances, a temporary treatment interruption or dose reduction may be necessary.
Patients should attend all recommended blood tests.
2. Hair Loss
Alopecia, or hair loss, is a reported adverse reaction associated with pemigatinib.
Patients may experience hair thinning or more noticeable hair loss during treatment.
The severity can differ between individuals.
Patients concerned about hair loss should discuss the symptoms with their healthcare professional. Supportive care may help manage the emotional and practical effects of changes in appearance.
3. Diarrhea
Diarrhea is another commonly reported adverse reaction.
It may involve frequent loose stools, abdominal discomfort or changes in normal bowel habits.
Persistent diarrhea can lead to dehydration and electrolyte disturbances.
Patients should contact their healthcare professional if diarrhea becomes severe, continues for an extended period or interferes with normal fluid intake.
Severe diarrhea may require medical management and a treatment adjustment.
4. Nail Disorders
Pemigatinib can cause nail-related adverse reactions.
These may include:
- Nail discoloration.
- Nail separation.
- Brittle nails.
- Changes in nail growth.
- Nail tenderness.
- Inflammation around the nails.
Patients should report painful or worsening nail changes.
Keeping nails clean and avoiding unnecessary injury may help reduce irritation.
5. Fatigue
Fatigue is a feeling of unusual tiredness or reduced energy.
It may affect daily activities, concentration and physical stamina.
Fatigue can result from the medicine, the underlying cancer or other medical conditions.
Patients should report persistent fatigue, especially when it interferes with normal activities.
The healthcare professional may evaluate blood tests, nutrition, hydration, sleep and other possible causes.
6. Nausea and Vomiting
Some patients experience nausea or vomiting while taking pemigatinib.
These symptoms may affect appetite, hydration and general comfort.
Patients should discuss persistent nausea or vomiting with their healthcare professional.
If vomiting occurs after taking pemigatinib, the U.S. reference-product instructions advise against taking an additional dose to replace the dose.
The next dose should be taken at the usual scheduled time.
Persistent vomiting or inability to maintain fluid intake may require medical assessment.
7. Constipation
Constipation may occur during treatment.
Patients may notice infrequent bowel movements, hard stools or discomfort when passing stools.
Persistent constipation should be discussed with a healthcare professional, especially if accompanied by severe abdominal pain, vomiting or abdominal swelling.
Treatment recommendations depend on the patient’s overall medical condition and other medicines.
8. Stomatitis and Mouth Inflammation
Stomatitis refers to inflammation inside the mouth.
It may cause soreness, irritation, discomfort or difficulty eating.
Patients should maintain appropriate oral hygiene and report painful or persistent mouth symptoms.
A healthcare professional may recommend supportive care or other treatment depending on the severity.
9. Dry Eyes
Pemigatinib may cause dry-eye symptoms.
Patients may experience irritation, a gritty sensation, discomfort or reduced tear production.
Persistent eye discomfort should be discussed with an eye-care professional or treating specialist.
Patients should also remain aware that pemigatinib can cause more serious ocular adverse reactions, including retinal pigment epithelial detachment.
10. Dry Mouth
Dry mouth may occur during treatment.
It can cause discomfort, difficulty swallowing dry foods or changes in taste.
Patients should discuss persistent symptoms with their healthcare professional, particularly if mouth dryness affects eating, drinking or oral health.
11. Changes in Taste
Some patients may experience changes in taste.
Food may taste different, less enjoyable or unusually bitter.
These changes can affect appetite and nutritional intake.
Patients should discuss persistent appetite or taste changes with their healthcare team.
12. Decreased Appetite
Reduced appetite is a reported adverse reaction.
Patients may eat less than usual or lose interest in food.
Unintentional weight loss or difficulty maintaining adequate nutrition should be discussed with the treating specialist.
13. Dry Skin and Skin Reactions
Pemigatinib may cause dry skin, rash or other skin-related symptoms.
Patients should report persistent irritation, worsening rash, painful skin changes or signs of infection.
The treating healthcare professional can determine whether additional treatment or dose modification is necessary.
14. Abdominal Discomfort and Joint Pain
Abdominal discomfort and joint pain have been reported during pemigatinib treatment.
The severity and duration may vary.
Persistent abdominal pain should not automatically be assumed to be a routine side effect because it may have other causes.
Patients should seek medical assessment for severe, worsening or unexplained abdominal symptoms.
Serious Side Effects of Pemigatinib
Some adverse reactions require particular attention because they may lead to significant complications.
| Adverse reaction | Important concern |
|---|---|
| Hyperphosphatemia | Excessive phosphate levels and possible soft-tissue mineralization |
| Retinal pigment epithelial detachment | Potential visual impairment |
| Other ocular toxicity | Changes in vision requiring assessment |
| Severe gastrointestinal symptoms | Risk of dehydration or complications |
| Serious skin reactions | Potential need for medical treatment |
| Embryo-fetal toxicity | Potential harm to an unborn child |
15. Retinal Pigment Epithelial Detachment
Retinal pigment epithelial detachment, or RPED, is an important ocular safety concern associated with pemigatinib.
It involves changes affecting the retinal pigment epithelium and may interfere with vision.
Symptoms may include blurred vision, visual floaters or other visual disturbances.
Patients should undergo recommended eye examinations, including OCT, before and during treatment.
New visual symptoms should be reported promptly.
16. Other Visual Disturbances
Patients may experience other changes in eyesight while taking pemigatinib.
These may include blurred vision or unusual visual sensations.
Any new or worsening visual problem should be assessed rather than assumed to be temporary.
An eye-care professional may recommend additional examinations or management.
17. Embryo-Fetal Toxicity
Pemigatinib may cause fetal harm.
Pregnancy status and reproductive plans should be discussed before treatment.
Under U.S. reference-product labeling, females of reproductive potential should use effective contraception during treatment and for one week after the final dose.
Patients who become pregnant while taking pemigatinib should contact their healthcare professional promptly.
Factors That May Affect Side Effects
Several factors can influence the likelihood and severity of adverse reactions.
These include:
- The treatment indication.
- The prescribed dose.
- The treatment schedule.
- Other medicines being taken.
- Kidney function.
- Liver function.
- Individual sensitivity.
- Overall health.
- Previous treatment history.
Patients should not compare their symptoms directly with another person’s experience because treatment responses can differ.
How Are Pemigatinib Side Effects Managed?
Management depends on the type and severity of the adverse reaction.
Healthcare professionals may recommend:
- Clinical assessment.
- Blood tests.
- Eye examinations.
- Supportive treatment.
- Dietary changes.
- Treatment interruption.
- Dose reduction.
- Permanent discontinuation when necessary.
The appropriate approach must be determined by the treating specialist.
Patients should not reduce or stop pemigatinib independently.
When Should Patients Contact a Doctor?
Patients should contact their healthcare professional if they experience persistent, worsening or unusual symptoms.
Prompt medical assessment is particularly important for:
- New blurred vision.
- Visual floaters or flashes of light.
- Severe or persistent diarrhea.
- Persistent vomiting.
- Significant dehydration.
- Severe abdominal pain.
- Severe skin reactions.
- Symptoms suggesting an allergic reaction.
- Other rapidly worsening health problems.
For an emergency, seek immediate medical care.
Can All Patients Experience the Same Side Effects?
No. Side effects differ between patients.
Some people may experience several adverse reactions, while others may experience only a few.
The absence of symptoms does not remove the need for routine monitoring.
Blood phosphate changes and ocular complications may require specific examinations even when a patient feels generally well.
Important Side Effect Reporting
Patients should communicate suspected adverse reactions to their treating healthcare professional.
Healthcare professionals can determine whether the symptoms are related to pemigatinib, the underlying disease, another medicine or another medical condition.
Suspected medicine-related adverse reactions may also be reported through the relevant national pharmacovigilance system or the responsible product authorization holder.
Conclusion
Pemigatinib may cause a range of adverse reactions, including hyperphosphatemia, hair loss, diarrhea, nail disorders, fatigue, nausea, mouth inflammation and eye problems.
Some side effects can be managed with monitoring and supportive treatment, while others may require dose modification or treatment interruption.
Regular blood tests, eye examinations and communication with the treating specialist are essential parts of safe treatment.
The information on this page describes pemigatinib-related adverse reactions and should not be interpreted as a prediction of an individual patient’s experience. Always follow the prescribing information for the actual product and the advice of a qualified healthcare professional.